Author of

• 20155

  +

  P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 692)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22651

    +

    P1.06-007 - EGFR Status Evaluation and Epidemiological Profile in Patients with NSCLC in a Brazilian Public Health Instituition (ID 8657)

    09:30 - 09:30  |  Author(s): C.D.S.M. Emerich
    • Abstract
    • Slides

    Background:
    Therapies targeting genetic alterations have improved response rates and overall survival for some patients with NSCLC (non small cell lung cancer) as agents against EGFR (epidermal growth factor receptor) actionable mutations. Is recommended to test all patients with advanced/metastatic non squamous NSCLC, but the rates of patients actually tested vary in different institiutions.The prevalence of EGFR mutations in non-squamous NSCLC population range from 15% to 40%. There is few data about EGFR mutations in the Brazilian population, which is known for ethnic heterogeneity. This study intends to report the rates of EGFR evaluation in advanced non-squamous NSCLC, as the prevalence and the profile of such mutations in a south brazilian public health instituition.
    
    Method:
    We performed an observational retrospective study including patients diagnosed with advanced non-squamous NSCLC between january 2011 to december 2016 at CEPON (Centro de Pesquisas Oncológicas). Their medical record have been reviewed and information regarding epidemiological profile as well as EGFR testing was retrieved.
    
    Result:
    345 patients were accrued. Targetable genetic alterations in EGFR were assessed in 74% (255/345) along the years and has a incremental pattern rising from only 22% of patients tested in 2011, 60% in 2012, 72% in 2013, 85% in 2014, to 100% of patients tested in 2015 and 2016. EGFR mutations were found in 18,03% (46/255) using the PCR COBAS method in tumoral tissue. EGFR mutations were more prevalent in women (30.09% vs. 9.60%; p < 0.001); and in never-smokers (49.12 vs. 9.58%; p < 0.001), but no significant difference was found regarding age under 50 year-old (27.66 vs. 17.28%; p = 0.159). The mean age of the mutated patients was 59 years (SD 11.82) with female predominance (74% vs. 26%). The most frequent genetic alteration detected was exon 19 deletion (50%), followed by L858R mutation (36%). Among the 46 patients with targetable EGFR mutation, 32 received getitinib or erlotinib in first or second line.
    
    Conclusion:
    Our findings shows that nowadays we have a good rate of screening of EGFR in advanced NSCLC. This improved over the years, reflecting the test availability, medical education with subespecialization, and easier acess to TKIs in CEPON. The prevalence of EGFR mutations in our population (18,03%) is slightly lower than the prevalence founded in other studies with brazilian patients (around 20%), maybe reflecting the european immigration in south of Brazil. Epidemiological profile is similar to previous studies showing EGFR mutation rates higher in female and non smokers patients.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.